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 Knee

Survivorship, complications,
and outcomes following distal
femoral arthroplasty for non-
neoplastic indications
Aims
Endoprosthetic reconstruction with a distal femoral arthroplasty (DFA) can be used to treat
distal femoral bone loss from oncological and non-oncological causes. This study reports the
short-term implant survivorship, complications, and risk factors for patients who underwent
DFA for non-neoplastic indications.

From Thomas Jefferson
Methods
University, Philadelphia, We performed a retrospective review of 75 patients from a single institution who underPennsylvania, USA
went DFA for non-neoplastic indications, including aseptic loosening or mechanical failure
of a previous prosthesis (n = 25), periprosthetic joint infection (PJI) (n = 23), and native or
periprosthetic distal femur fracture or nonunion (n = 27). Patients with less than 24 months’
follow-up were excluded. We collected patient demographic data, complications, and reoperations. Reoperation for implant failure was used to calculate implant survivorship.

Results
Overall one- and five-year implant survivorship was 87% and 76%, respectively. By indication
for DFA, mechanical failure had one- and five-year implant survivorship of 92% and 68%, PJI
of 91% and 72%, and distal femur fracture/nonunion of 78% and 70% (p = 0.618). A total of
37 patients (49%) experienced complications and 27 patients (36%) required one or more
reoperation. PJI (n = 16, 21%), aseptic loosening (n = 9, 12%), and wound complications (n
= 8, 11%) were the most common complications. Component revision (n = 10, 13.3%) and
single-stage exchange for PJI (n = 9, 12.0 %) were the most common reoperations. Only
younger age was significantly associated with increased complications (mean 67 years (SD
9.1)) with complication vs 71 years (SD 9.9) without complication; p = 0.048).

Conclusion
DFA is a viable option for distal femoral bone loss from a range of non-oncological causes,
demonstrating acceptable short-term survivorship but with high overall complication rates.
Cite this article: Bone Jt Open 2022;3-3:173–181.
Keywords: Distal femoral replacement, Megaprosthesis, Distal femur, Fracture, Periprosthetic joint infection, Mechanical failure, Trauma, Total
joint
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Over the last two decades, the number of
primary and revision total knee arthroplasties (TKAs) performed in the USA, and the
resultant economic burden, have increased
dramatically and are projected to continue to
rise.1,2 This has led to an increase in patients
with distal femoral bone loss relating to osteolysis, component failure, periprosthetic joint
infection (PJI), periprosthetic distal femur

fractures, and cumulative loss from multiple
revisions.3-5 There is debate around how best
to address these defects. Traditionally, distal
femoral bone loss has been managed with
augmentation (cones and/or sleeves),6,7
structural allografts,5,8 modular prostheses,9
and endoprosthetic replacement (EPR) in the
form of distal femoral arthroplasty (DFA).
4,10-12
Compared to the salvage alternatives of
arthrodesis and amputation, endoprostheses
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Table I. Demographic details of patients undergoing distal femoral arthroplasty, subdivided by surgical indication.
Variable

Mech failure (n = 25) PJI (n = 23)

Fracture (n = 27)

All (n = 75)

p-value

Mean age, yrs (SD)

68.9 (9.5)

64.8 (9.5)

72.9 (8.9)

69.1 (9.7)

0.012†

Female, n (%)

13 (52)

12 (52)

22 (78)

47 (63)

0.041‡

Mean BMI, kg/m2 (SD)

33.7 (6.0)

32.4 (7.6)

32.6 (10.9)

32.9 (8.4)

Mean CCI* (SD)

0.83 (0.98)

1.05 (1.82)

0.58 (1.06)

Mean ASA grade (SD)

2.8 (0.4)

2.9 (0.4)

2.75 (0.4)

Diabetes mellitus, n (%)

5 (20)

2 (9)

5 (18)

Rheumatoid arthritis, n (%)
Active smoker, n (%)
Mean no. prior knee surgeries (SD)

0
11 (44)
3.5 (2.6)

0.81 (1.31)
2.8 (0.4)
12 (16)

0.847†
0.456†
0.414†
0.512‡

1 (4)

2 (7)

3 (4)

0.394‡

9 (39)

10 (37)

30 (40)

0.872‡

4.6 (1.7)

1.5 (0.9)

3.1 (2.3)

< 0.001†

*Age was not adjusted.
†Analysis of variance.
‡Chi-squared test.
ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; SD, standard deviation.

demonstrate improved cost-
effectiveness, more rapid
recovery, earlier weightbearing, and superior psychological, physical, and functional outcomes.10,13-15 Despite
high complication rates, the benefits of megaprosthesis
implantation in revision knee arthroplasty have been
shown to outweigh the risks.10,13 For these reasons, EPR
has become increasingly popular for non-
neoplastic
indications.9-11
There is additional interest in DFA in the setting of geriatric distal femoral fractures. To date, DFA is considered
primarily in highly comminuted intra-articular fractures,
patients with severe pre-
existing knee arthritis, those
with periprosthetic fracture with a loose component or
inadequate distal bone stock for fixation, and those with
fracture non- or malunion.16,17 These often low-energy
fractures occur in a similar patient population as low-
energy hip fractures, and have reported nonunion rates
of up to 24% following open reduction internal fixation
(ORIF),18 with up to 25% one-year mortality rates. Treatment with internal fixation often requires prolonged
limited weightbearing in this already susceptible population. Arthroplasty for displaced geriatric femoral neck
fractures has demonstrated improved functional scores
and decreased revision rates when compared to ORIF.19,20
There is early suggestion DFA in geriatric native distal
femur fractures may have similar benefits: it has shown
decreased rates of wheelchair dependence at one year
(0% vs 23%) compared to ORIF, albeit without significant
differences in reoperation rate.16 In periprosthetic distal
femur fractures deemed unfixable, DFA had decreased
estimated blood loss (EBL), operating time, and length of
hospital stay compared to reconstruction with allograft-
prosthesis composite, or revision components with
augments.21 The major downside of EPR is the potential
complications of infection, aseptic loosening, implant
mechanical failure, and periprosthetic fracture.4,12,22-24
Published literature has shown favourable outcomes
following DFA in patients with oncological indications;25,26 however, there is a scarcity of studies describing

megaprosthesis use and outcomes for non-oncological
reconstructions. The primary aim of this study was
to determine the survivorship, complications, and
outcomes for patients who presented to our institution
with non-neoplastic disease for DFA. The secondary aim
was to identify predictors and risk factors that influenced
postoperative outcomes.

Methods
Demographic data. We performed a retrospective review
to identify all cases of DFA performed at our single institution between January 2002 and April 2019. Included in
this study were patients with minimum two-year clinical
follow-up and non-neoplastic indications for DFA, including acute native and periprosthetic distal femoral fracture, distal femoral nonunion, PJI, and aseptic loosening
or mechanical failure of a previous prosthesis. This study
was approved by our institutional review board.
Overall, 75 patients met the inclusion criteria. The
demographic details of the study’s population are shown
in Table I. For analysis, indications for DFA were categorized as mechanical failure (n = 25), PJI (n = 23), and
trauma (n = 27). Within the trauma group, 20 (74%) of
distal femur fractures were periprosthetic and 7 (26%)
were in native femora.
Surgical data. In the cohort, three types of implants were
used: 61 Global Modular Arthroplasty System (GMRS;
Stryker, USA), 11 Limb Preservation System (LPS; Depuy
Synthes, USA), and three Orthopaedic Salvage System
(OSS; Zimmer Biomet, USA). Implant type as well as the
use of adjunctive fixation options, such as hydroxyapatite (HA) collar, cone, and sleeve choice, were based on
surgeon preference. In 70 patients the DFA component
was cemented, and in five it was press-fit. All patients received a rotating hinge implant. A total of 19 patients’
implants included segmental modular extension components for distal femoral length. The mean operating time
for the entire cohort was 172 minutes (standard deviation
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Fig. 1
Kaplan-Meier survival curve for all patients’ status post-distal femoral arthroplasty for non-oncological indications, with endpoint of time until first
reoperation for implant revision (95% confidence interval 7.73 to 9.97).

(SD) 49.1) and the mean estimated blood loss (EBL) was
461 ml (SD = 790).
Radiological data. The Anderson Orthopaedic Research
Institute (AORI) classification was used preoperatively
based on radiograph images to determine degree of femoral bone loss in each patient. Overall, 16 were type 2 A,
17 type 2B, and 42 type C.27
Follow-up data. The clinical follow-
up duration was recorded for all patients. The mean follow-up duration was
60.3 months (SD 35.8; 24.2 to 203). The Kaplan-Meier
survivorship analysis was only performed using patients
who fulfilled the minimum two-year clinical follow-up.
Statistical analysis. The rates of complications and reoperations were determined from hospital electronic medical record (EMR) notes and physician follow-up records.
Survivorship of the DFA was established using Kaplan-
Meier curves with revision as the endpoint.28 Survival
was calculated for the entire cohort as well as for each
category of surgical indication. All p-values for parametric data were calculated using independent-
samples
t-test or analysis of variance (ANOVA), and all nonparametric data were calculated using the Mann-Whitney U
test. All p-values for categorical data were calculated using Fisher’s exact test or chi-squared test. All p-values for
Kaplan meier curves were calculated using log rank test.
The mean and SD were calculated for age, BMI, previous
surgeries, and CCI. All analyses were performed using R
studio software version 3.5.1 (R Foundation for Statistical
Computing, Austria).

Results

Survivorship. With any implant revision, including poly-

ethylene exchange, as the final endpoint, Kaplan-Meier
VOL. 3, NO. 3, MARCH 2022

analysis of the 75-patient cohort (95% CI 7.73 to 9.97)
demonstrated a survival rate of 87% at one year and 76%
at five years (Figure 1). Patients with an original indication of mechanical failure (n = 25 (95% CI 5.28 to 9.96))
demonstrated a survival rate of 92% at one year and 68%
at five years. Those with an indication for PJI (n = 23 (95%
CI 7.50 to 11.8)) had a one-year survival rate of 91% and
a five-year survival rate of 72%. Patients with an initial
indication of trauma (n = 27 (95% CI 6.11 to 9.64)) had a
one-year survival rate of 78% and a five-year survival rate
of 70% (Figure 2). There was no statistically significant
difference between groups (p = 0.618).
With any reoperation as the endpoint, Kaplan-Meier
analysis of the 75-patient cohort (95% CI 5.81 to 8.66)
demonstrated a survival rate of 77% at one year and 62%
at five years (Figure 3). Patients with an original indication of mechanical failure (n = 25 (95% CI 4.60 to 8.81))
demonstrated a survival rate of 80% at one year and 70%
at five years. Those with an indication for PJI (n = 23 (95%
CI 6.08 to 10.9)) had a one-year survival rate of 83% and
a five-year survival rate of 63%. Patients with an original
indication of trauma (n = 27 (95% CI 4.67 to 8.57)) had a
one-year survival rate of 70% and a five-year survival rate
of 56% (Figure 4). There was no statistically significant
difference between groups (p = 0.630).
Complications and reoperations. A total of 38 patients
(51%) did not experience any complications. For the remaining patients, ten (13%) had complications managed
exclusively nonoperatively, while 27 (36%) had at least
one reoperation (Table II). There were 13 patients (17%)
who underwent multiple reoperations (Table III). Broken
down by initial indication for DFA, the mechanical failure
cohort had 14 (56%) patients with any complications,
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Fig. 2

Kaplan-Meier survival curve for patients status post-distal femoral arthroplasty for non-oncological indications, subdivided by initial indication for
megaprosthesis, with endpoint of time until first reoperation for implant revision. Patients with an original indication of mechanical failure (n = 25): 95%
confidence interval (CI) 5.28 to 9.96; periprosthetic joint infection (PJI) (n = 23): 95% CI 7.50 to 11.8; and trauma (n = 27): 95% CI 6.11 to 9.64.

Fig. 3
Kaplan-Meier survival curve for all patients status post-distal femoral arthroplasty for non-oncological indications, with endpoint of time until first reoperation
for any cause (95% confidence interval 5.81 to 8.66).

with nine (36%) undergoing a total of 23 additional surgeries. PJI was again the most common complication,
occurring in six (24%) patients. Two patients underwent
knee arthrodesis and two patients underwent above-
knee amputations. The PJI cohort had 12 (52%) patients
with one or more complication, with five (22%) managed nonoperatively and seven (30%) underdoing a total of 21 additional surgeries. Recurrent PJI was the most
common complication, occurring in five (22%) patients.

One patient underwent knee arthrodesis, and one underwent above-knee amputation. The trauma cohort had 11
(41%) patients with any complications, with all 11 undergoing at least one reoperation for a total of 24 additional
surgeries. PJI was again the most common complication,
occurring in five (19%) patients. Three patients underwent above-knee amputations. Overall, among the entire population the most common complications were PJI
(n = 16, 21%), aseptic loosening (n = 9, 12%), and wound
BONE & JOINT OPEN
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Fig. 4
Kaplan-Meier survival curve for patients status post-distal femoral arthroplasty for non-oncological indications, subdivided by initial indication for
megaprosthesis, with endpoint of time until first reoperation for any cause. Patients with an original indication of mechanical failure (n = 25): 95% confidence
interval (CI) 4.60 to 8.81; periprosthetic joint infection (PJI) (n = 23): 95% CI 6.08 to 10.9; and trauma (n = 27): 95% CI 4.67 to 8.57.

Table II. All complications following distal femoral arthroplasty, by initial
surgical indication.
Indication, n (%)
Complication

Mech fail
(n = 25)

PJI
(n = 23)

Fracture
(n = 27)

Total complications

14 (56)

12 (52)

11 (41)

PJI

6 (24)

5 (22)

5 (18)

Aseptic loosening

4 (16)

4 (17)

2 (7)

Wound complication

3 (12)

2 (9)

3 (11)

Surgical site infection

2 (8)

1 (4)

1 (4)

Periprosthetic fracture

1 (4)

3 (13)

2 (7)

Extensor mechanism disruption

1 (4)

3 (13)

0 (0)

Haematoma

0 (0)

3 (13)

0 (0)

Nerve palsy

1 (4)

1 (4)

0 (0)

Dislocation

0 (0)

0 (0)

1 (4)

Arthrofibrosis

0 (0)

0 (0)

1 (4)

PJI, periprosthetic joint infection.

complications (n = 8, 11%). Of the factors analyzed, only
younger age was significantly associated with increased
risk of complication (Table IV).
The mean time until the first reoperation was
21.1 months (SD 34.0). The types of reoperations varied
based upon indication for surgery (Table III). The most
common reoperations throughout the entire population were component revision (13.3 %) and single-stage
exchange for PJI (12.0 %). The mean time to explant in
those whose implant failed was 27.3 months (SD 36.7).

Discussion

As the volume of patients with distal femoral bone loss
increases, it is imperative that the arthroplasty surgeon
be knowledgeable on outcomes of available treatment
VOL. 3, NO. 3, MARCH 2022

methods. The aim of this study was to identify whether
DFA for non-
neoplastic indications allows for acceptable outcomes and prosthesis survivorship in patients
presenting with extreme distal femoral bone loss, and to
report on predictive factors for prosthesis outcomes. It
highlights the efficacy of DFA in these challenging cases,
and identifies differing outcomes based on the indication
for DFA, with trauma showing a non-significant decrease in
implant survivorship at one and five years. The severity of
complications also varied, with DFA indicated for trauma or
mechanical loosening, resulting in higher rates of arthrodesis or amputation compared to DFA for PJI.
Distal femoral bone loss and fracture occur disproportionately in geriatric populations.1,2 These patients are
prone to prolonged bed rest and partial weightbearing
periods, increasing their risk of associated complications
such as deconditioning, falls, pneumonia, and venous
thromboembolism following surgery.29,30 Though used,
megaprosthesis for these indications is an exceptional indication, as demonstrated by the small number of cases and
limited published work on the procedure. In fact, the decision to place a megaprosthesis is sometimes only made
during surgery.4,31 This decision is based on intraoperative factors such as bone quality, nonunion, and damage
observed following cement spacer or existing prosthesis
removal, and may differ from the original plan based on
preoperative imaging and exam. A key benefit of DFA is
the ability for early or immediate postoperative weightbearing and range of motion. In most cases, the pathologies necessitating megaprosthetic reconstruction are in
fact limb- and even life-threatening. Previous research has
shown that lower limb salvage is feasible for a majority of
patients, thus sparing them the negative psychological,
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Table III. Reoperations following distal femoral arthroplasty, by initial surgical indication.
 Variable
 
Patients undergoing reoperations, n (%)
Total reoperations

Indication
Mech fail (n = 25)

PJI (n = 23)

9 (36)

7 (30)

Trauma (n = 27)
11 (41)

23

21

24

One reoperation

3

3

8

Two reoperations

3

1

1

Three reoperations

0

1

0

Four reoperations

2

0

0

Five reoperations

0

0

0

Six reoperations

1

1

1

Seven reoperations

0

1

1

Single-stage exchange (PJI), n (%)

4 (17)

4 (19)

2 (8)

Revision (aseptic loosening), n (%)

4 (17)

4 (19)

3 (12)

Irrigation and debridement (infection), n (%)

4 (17)

0 (0)

9 (38)

Amputation, n (%)

2 (9)

1 (5)

3 (12)

Explant and antibiotic spacer, n (%)

2 (9)

3 (14)

3 (12)

Irrigation and debridement (wound), n (%)

3 (13)

2 (10)

1 (4)

Knee arthrodesis, n (%)

3 (13)

1 (5)

0 (0)

Spacer removal and reimplantation, n (%)

1 (4)

2 (10)

0 (0)

Flap, n (%)

0 (0)

0 (0)

1 (4)

ORIF, n (%)

0 (0)

1 (5)

0 (0)

Other, n (%)

0 (0)

3 (14)

1 (4)

ORIF, open reduction internal fixation; PJI, periprosthetic joint infection

social, physical, and functional effects associated with
amputation.4,32-34
The survivorship of our entre cohort, regardless of indications, was 87% at one year and 76% at five years. In an
earlier published series of 37 patients who received 39
DFAs for non-neoplastic indications, Berend and Lombardi4
reported a 12-month implant survivorship of 97% at and
a 46-
month implant survivorship of 87%. This study’s
rate was 87% at one year and 78% at 46 weeks, lower
than survivorship reported in other studies. Perhaps this
lower value reflects the larger number of patients in our
cohort with a history of PJI and the higher mean number
of previous surgeries on the knee. Although the survivorship numbers appear to be low, they are higher than the
one- and five-
year survivorship of other rotating hinge
prostheses that are used in salvage revision TKA. 35,36Additionally, the limb salvage was ultimately successful in 92%
(n = 69) of patients, similar to the previously reported 95%
by Berend and Lombardi.
When looking at survivorship based on indication, our
study showed one- and five-year implant survivorship for
mechanical failure of 92% and 68%, PJI of 91% and 72%,
and distal femur fracture/nonunion of 78% and 70% (p =
0.618, log-rank test). We were underpowered and unable
to detect a significant difference in survivorship between
cohorts; however, there are no current studies comparing
these three indications. Although low, our survivorship and
cohort size compare to recently published literature on a
cohort-to-cohort basis (Table V). For PJI (n = 41), Theil et
al37 reported 66% survivorship at two years and 50% at five

Table IV. Complications following distal femoral arthroplasty by patient
and surgical factors.
Factor

No complication
(n = 38)

Complication
(n = 37)

p-value

Mean age, yrs (SD)

71.2 (9.9)

66.8 (9.1)

0.049†

Female, n (%)

27 (71)

20 (54)

0.128‡

Mean BMI, kg/m2
(SD)

32.3 (8.9)

33.6 (7.8)

0.504†

Mean CCI* (SD)

0.94 (1.2)

0.65 (1.5)

0.358†

Mean ASA grade (SD) 2.8 (0.5)

2.8 (0.4)

1.000†

Diabetes Mellitus,
n (%)

6 (16)

1.000‡

1 (2.7)

1.000‡

6 (16)

Rheumatoid arthritis, 2 (5)
n (%)
Active smoker, n (%) 17 (45)

13 (35)

0.396‡

Mean no. prior knee 3.1 (2.4)
surgeries (SD)

3.1 (2.1)

1.000†

Estimated blood loss, 512 (1,068)
ml (SD)

407 (298)

0.566†

Operating time, mins 162 (40)
(SD)

183 (56)

0.065†

*Not age-adjusted.
†Independent-samples t-test.
‡Chi-squared test.
ASA, American Society of Anesthesiologists score; CCI, Charlson
Comorbidity Index; SD, standard deviation.

years. Matar et al38 reported a five-year, 80% survivorship
for a cohort composed of patients who underwent DFA for
PJI (n = 16) and aseptic loosening (n = 17).
Other options for knee reconstruction are available
for patients in need of lower limb preservation. One
BONE & JOINT OPEN
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Fig. 5
Pre- and postoperative anteroposterior radiographs of a 60-year-old female with prior total knee arthroplasty (2009) and periprosthetic joint infection (PJI)
and revision (2010) presenting with a) imaging of her existing total knee arthroplasty. b) Six years after the revision knee arthroplasty and multiple failed
antibiotic courses for recurrent methicillin-sensitive Staphylococcus aureus PJI, the implant was explanted and an antibiotic cement spacer was placed. c) Four
months later she underwent distal femoral arthroplasty (DFA). d) Due to suspected ongoing PJI she then underwent a polyethylene exchange and irrigation
and debridement three weeks later. e) Without resolution of the PJI, she underwent DFA explantation and placement of antibiotic spacer after another two
months and, lastly, f) after an additional three months she underwent arthrodesis of the right knee. There have been no signs of PJI since fusion.

Table V. Summary of cited literature data for use of distal femoral arthroplasty in non-oncological patients.
Study

Indication for DFA

Present study

Median follow-
Patients, n up, mths

Complication Reoperation
rate, %
rate, %

Survivorship
1 yr, %

Survivorship
5 yrs, %

75

60

49

36

87

76

Fracture/nonunion

27

-

41

41

78

70

PJI

23

-

52

30

91

72

Aseptic loosening/mechanical 25
failure

-

56

36

92

68

Theil et al37

PJI

41

59

-

47

Matar et al39

Periprosthetic fracture

27

48

Matar et al38

3.7

66 at 2 yrs

50

-

-

33

60

12

-

-

80

PJI

16

-

-

-

-

-

Aseptic loosening

17

-

-

-

-

-

37

46

18

14

97

83

Revision TKA

11

-

-

-

-

-

Fracture/nonunion

15

-

-

-

-

-

Aseptic loosening/mechanical
failure

11

-

-

-

-

-

21

Berend and
Lombardi4

34

55

24

-

-

5

-

-

-

-

-

Fracture/nonunion

14

-

57

-

-

-

Aseptic loosening

2

-

-

-

-

-

59

46

23

-

-

Höll et al13
PJI

Mortazavi et al40

7.4

Periprosthetic fracture

22

Dashes signify that a particular data point was not reported in the cited work.
DFA, distal femoral arthroplasty; PJI, periprosthetic joint infection.

commonly used method is a structural allograft. However,
complications following this procedure occur in 23% to
55% of cases and may include resorption, nonunion,
and infection.9,13,41–43 Perhaps the worst impediment of
the allograft is the varying time it takes for the patient
to become weightbearing.44 In this series of 75 patients,
49% (n = 37) suffered at least one complication, with
nine patients (13%) needing revisions. This is consistent
with other published literature, showing overall complication rates following DFA of up to 46% for periprosthetic
fracture as the presenting indication,40 and 55% across
VOL. 3, NO. 3, MARCH 2022

all non-
oncological indications.13 Revisions have been
shown to range from 4% in patients with DFA for periprosthetic fracture to 18% for all patients who underwent
DFA without tumour indications.4,13,39
PJI was the most common complication. A total of 16
(21.3%) of our patients experienced PJI following implantation of their megaprosthesis (Figure 5). Though high,
this rate is mirrored in published literature describing rates
of PJIs with megaprostheses, with reported rates of 20%
following DFA.13,45 In our study, PJI was a major driver of
implant survivorship failure (n = 13). Another common
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complication in this study was aseptic loosening. A study
by Myers et al10 reported an aseptic loosening rate of
35% following prostheses over a period of ten years.
The loosening rate in this study was predictably lower
at only 12%, due to shorter follow-up time. However, in
our study, loosening was a driver for survivorship failure.
Overall, an increase in aseptic loosening can be expected
with longer follow-up durations, and may decrease in
populations with limited walking capacity.6,13
This study has several limitations. The number of
patients for each surgical indication is small, and powered
analysis could not be conducted due to the infrequent
performance of this procedure, though the size of each
group is similar to reported populations in other studies.
Additionally, it was a retrospective analysis and lacked a
control group. Furthermore, despite our attempts, we
were not able to obtain enough patient-reported pre- and
postoperative functional outcome scores to include in this
study. We suspect this is due to the length of our inclusion
timeframe (starting in 2002), which may mean patients
further removed from their procedure have since become
mentally incapacitated or deceased.
This topic has much potential for future study. The field
of arthroplasty would benefit greatly from an appropriately powered prospective comparison of the treatment
options for distal femoral bone loss for each of the previously
discussed indications, with inclusion of functional outcomes.
Another area of future study is research into techniques for
limiting aseptic loosening following DFA, possibly with
methods such as press fitting implants, the use of cones/
sleeves, or using hybrid cemented fixation.
To summarize, in this retrospective cohort study, we
demonstrated that DFA is a viable surgical option for those
patients with significant distal femoral bone loss or fracture.
Patients should be counselled preoperatively about relatively
high complications rates, likelihood of implant survivorship,
and the reality of the often limb-threatening nature of their
diagnoses.
Take home message

-- Distal femoral arthroplasty (DFA) is a viable option for
significant non-oncological distal femoral bone loss.
-- Patients who underwent DFA for mechanical failure
demonstrated the highest survivorship as well as highest complication
rate.
-- Those who underwent DFA for trauma and its sequelae demonstrated
the highest failure rate.
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